189 related articles for article (PubMed ID: 9817177)
1. Predictors of adherence to tuberculosis treatment in a supervised therapy programme for prisoners before and after release. Study Group of Adherence to Tuberculosis Treatment of Prisoners.
Marco A; Caylà JA; Serra M; Pedro R; Sanrama C; Guerrero R; Ribot N
Eur Respir J; 1998 Oct; 12(4):967-71. PubMed ID: 9817177
[TBL] [Abstract][Full Text] [Related]
2. Prevalence of latent tuberculosis infection in inmates recently incarcerated in a men's prison in Barcelona.
Marco A; Solé N; Orcau A; Escribano M; del Baño L; Quintero S; Caylà JA
Int J Tuberc Lung Dis; 2012 Jan; 16(1):60-4. PubMed ID: 22236847
[TBL] [Abstract][Full Text] [Related]
3. Factors predicting non-completion of tuberculosis treatment among HIV-infected patients in Barcelona (1987-1996).
Tangüis HG; Caylà JA; García de Olalla PG; Jansà JM; Brugal MT
Int J Tuberc Lung Dis; 2000 Jan; 4(1):55-60. PubMed ID: 10654645
[TBL] [Abstract][Full Text] [Related]
4. Tuberculosis treatment outcome and predictors in northern Ethiopian prisons: a five-year retrospective analysis.
Adane K; Spigt M; Dinant GJ
BMC Pulm Med; 2018 Feb; 18(1):37. PubMed ID: 29463234
[TBL] [Abstract][Full Text] [Related]
5. Treatment outcomes of tuberculosis patients in Brazilian prisons: a polytomous regression analysis.
Ribeiro Macedo L; Reis-Santos B; Riley LW; Maciel EL
Int J Tuberc Lung Dis; 2013 Nov; 17(11):1427-34. PubMed ID: 24125446
[TBL] [Abstract][Full Text] [Related]
6. [Prevalence of human immunodeficiency virus type 1 and Mycobacterium tuberculosis infections in a prison population in the years 1989 to 1995].
Pérez-Agudo F; Alonso Moreno FJ; Urbina Torija J
Med Clin (Barc); 1998 Feb; 110(5):167-70. PubMed ID: 9547719
[TBL] [Abstract][Full Text] [Related]
7. Mycobacterium tuberculosis and human immunodeficiency virus co-infection in intravenous drug users on admission to prison.
Martín V; Caylà JA; Bolea A; Castilla J
Int J Tuberc Lung Dis; 2000 Jan; 4(1):41-6. PubMed ID: 10654643
[TBL] [Abstract][Full Text] [Related]
8. Tuberculosis incidence and treatment completion among Ugandan prison inmates.
Schwitters A; Kaggwa M; Omiel P; Nagadya G; Kisa N; Dalal S
Int J Tuberc Lung Dis; 2014 Jul; 18(7):781-6. PubMed ID: 24902552
[TBL] [Abstract][Full Text] [Related]
9. Adherence to Antiretroviral Therapy and Tuberculosis Treatment in a Prison of Tehran, Iran.
Seyed Alinaghi SA; Farhoudi B; Mohraz M; Alipour A; Golrokhy R; Hosseini M; Miri J
Infect Disord Drug Targets; 2016; 16(3):199-203. PubMed ID: 27311561
[TBL] [Abstract][Full Text] [Related]
10. The effects of increasing incentives on adherence to tuberculosis directly observed therapy.
Davidson H; Schluger NW; Feldman PH; Valentine DP; Telzak EE; Laufer FN
Int J Tuberc Lung Dis; 2000 Sep; 4(9):860-5. PubMed ID: 10985655
[TBL] [Abstract][Full Text] [Related]
11. Tuberculosis treatment outcomes among prisoners and general population in Zomba, Malawi.
Singano V; Kip E; Ching'ani W; Chiwaula L
BMC Public Health; 2020 May; 20(1):700. PubMed ID: 32414357
[TBL] [Abstract][Full Text] [Related]
12. Tuberculosis in London: the importance of homelessness, problem drug use and prison.
Story A; Murad S; Roberts W; Verheyen M; Hayward AC;
Thorax; 2007 Aug; 62(8):667-71. PubMed ID: 17289861
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness of isoniazid treatment for latent tuberculosis infection among human immunodeficiency virus (HIV)-infected and HIV-uninfected injection drug users in methadone programs.
Scholten JN; Driver CR; Munsiff SS; Kaye K; Rubino MA; Gourevitch MN; Trim C; Amofa J; Seewald R; Highley E; Fujiwara PI
Clin Infect Dis; 2003 Dec; 37(12):1686-92. PubMed ID: 14689352
[TBL] [Abstract][Full Text] [Related]
14. Tuberculosis in European cities: establishment of a patient monitoring system over 10 years in Paris, France.
Farge D; Porcher R; Antoun F; Fain O; Keshtmand H; Rocher G; Mallet HP; Rambeloarisoa J; Gerber F; De Castro N; Che D; Coulombier D; Zaleskis R; Herrmann JL; Dye C;
Int J Tuberc Lung Dis; 2007 Sep; 11(9):992-8. PubMed ID: 17705977
[TBL] [Abstract][Full Text] [Related]
15. Tuberculosis, HIV seroprevalence and intravenous drug abuse in prisoners.
Drobniewski FA; Balabanova YM; Ruddy MC; Graham C; Kuznetzov SI; Gusarova GI; Zakharova SM; Melentyev AS; Fedorin IM
Eur Respir J; 2005 Aug; 26(2):298-304. PubMed ID: 16055879
[TBL] [Abstract][Full Text] [Related]
16. Pulmonary and extrapulmonary tuberculosis at AIDS diagnosis in Spain: epidemiological differences and implications for control.
Castilla J; Gutiérrez A; Guerra L; Pérez de la Paz J; Noguer I; Ruiz C; Belza MJ; Cañón J
AIDS; 1997 Nov; 11(13):1583-8. PubMed ID: 9365762
[TBL] [Abstract][Full Text] [Related]
17. Predictors for multidrug-resistant tuberculosis among HIV-infected patients and response to specific drug regimens. Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA) and the AIDS Clinical Trials Group (ACTG), National Institutes for Health.
Telzak EE; Chirgwin KD; Nelson ET; Matts JP; Sepkowitz KA; Benson CA; Perlman DC; El-Sadr WM
Int J Tuberc Lung Dis; 1999 Apr; 3(4):337-43. PubMed ID: 10206505
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness of supervised, intermittent therapy for tuberculosis in HIV-infected patients.
Alwood K; Keruly J; Moore-Rice K; Stanton DL; Chaulk CP; Chaisson RE
AIDS; 1994 Aug; 8(8):1103-8. PubMed ID: 7986406
[TBL] [Abstract][Full Text] [Related]
19. [Treatment of tuberculosis: compliance, dropouts and supervised treatments].
Lobo Barrero CA; Pérez Escolano E
Arch Bronconeumol; 1997 Dec; 33(11):588-90. PubMed ID: 9508475
[No Abstract] [Full Text] [Related]
20. Outcome of pulmonary tuberculosis treatment in the tertiary care setting--Toronto 1992/93. Tuberculosis Treatment Completion Study Group.
Wobeser W; Yuan L; Naus M
CMAJ; 1999 Mar; 160(6):789-94. PubMed ID: 10189422
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
